Abstract | BACKGROUND: METHODS: Patients with cytologically documented ALN metastases from inflammatory breast carcinoma were treated in three prospective primary chemotherapy trials. After surgery, patients were subdivided into those patients with and those patients without residual ALN carcinoma. Survival was calculated using the Kaplan-Meier method. RESULTS: Of 175 patients treated, 61 had cytologically confirmed ALN metastases. Fourteen patients (23%) achieved a pCR of the ALNs after primary chemotherapy. The 5-year OS and RFS rates were found to be improved in those patients achieving a pCR of the ALNs (82.5% [95% confidence interval (95% CI), 62.8-100%] and 78.6% [95%CI, 59.8-100%], respectively, vs. 37.1% [95%CI, 25.4-54.2%] and 25.4% [95%CI, 15.5-41.5%], respectively) (P = 0.01 [for OS] and P = 0.001 [for RFS]). Combination anthracycline and taxane-based primary chemotherapy resulted in significantly more patients achieving an ALN pCR (45% vs. 16%; P = 0.01). CONCLUSIONS:
|
Authors | Bryan T Hennessy, Ana Maria Gonzalez-Angulo, Gabriel N Hortobagyi, Massimo Cristofanilli, Shu Wan Kau, Kristine Broglio, Bruno Fornage, S Eva Singletary, Aysegul Sahin, Aman U Buzdar, Vicente Valero |
Journal | Cancer
(Cancer)
Vol. 106
Issue 5
Pg. 1000-6
(Mar 01 2006)
ISSN: 0008-543X [Print] United States |
PMID | 16444747
(Publication Type: Clinical Trial, Journal Article)
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Breast Neoplasms
(drug therapy, pathology)
- Carcinoma
(drug therapy, pathology)
- Disease-Free Survival
- Female
- Follow-Up Studies
- Humans
- Inflammation
- Lymphatic Metastasis
- Middle Aged
- Treatment Outcome
|